Using Available Evidence And Guidelines For Managing An Evolving AML Treatment Paradigm ClinicalXchange Oncology Podcasts podcast

コンテンツは Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャストコンテンツは、Clinical Care Solutions and CCS ClinicalXchange Oncology Podcast またはそのポッドキャストプラットフォームパートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。

ClinicalXchange Oncology podcasts «
Using Available Evidence and Guidelines for Managing an Evolving AML Treatment Paradigm

3y ago 27:20

MP3•エピソードのホーム

Presenter:

Gail J. Roboz MD
Professor of Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
New York-Presbyterian Hospital
New York, New York, United States

This brief program will begin with a review of NCCN Guidelines® Recommendations for the treatment of AML in individuals 60 years of age or older. Next, the results of the BRIGHT AML 1003 trial comparing glasdegib + LDAC to LDAC alone, the VIALE-A trial comparing venetoclax + azacitidine vs azacitidine alone, and a comparison of CPX-351 vs standard of care cytarabine + daunorubicin (7 + 3 regimen) for induction and consolidation, will be reviewed. The faculty will discuss FLT3 and IDH inhibitor approvals for AML, IDK differentiation syndrome, and measuring MRD in AML. Finally, results of a trial examining oral azacitidine and a meta-analysis of 5 trials examining gemtuzumab ozogamicin will be reviewed.https://www.clinical-care.org/resource-center-details/using-available-evidence-and-guidelines-for-managing-an-evolving-aml-treatment-paradigm

Follow along with the slideset located here:
https://bit.ly/3lJNHYC

4 つのエピソード